Leerink Partners analyst Andrew Berens has maintained their neutral stance on ZNTL stock, giving a Hold rating on February 28.
Andrew Berens has given his Hold rating due to a combination of factors surrounding Zentalis Pharmaceuticals’ recent financial results and pipeline updates. While all programs are progressing as previously guided, the expected final results from the Phase 1 combination treatment in osteosarcoma, due in the first half of 2024, are viewed mostly as a speculative opportunity due to the small size of the target market. Additionally, Berens likely considers the anticipated release of the Phase 3 trial details for first-line platinum-sensitive ovarian cancer maintenance treatment in the second half of 2024, which focuses on a subset of patients who are ineligible for current maintenance therapies.
Berens’ assessment also takes into account the scheduled clinical updates for the second half of 2024, including initial data on the Bcl-2 inhibitor and azeno combination in relapsed/refractory AML, and the topline Phase 2 data from the MAMMOTH trial targeting PARPi resistant ovarian cancer. Moreover, the expected data from various Phase 1 and Phase 2 trials in solid tumors and gynecologic malignancies in the coming years align with Zentalis’ guidance. The company’s financial position, with a reported cash and cash equivalents sufficient to fund their operations, adds another layer of consideration to the Hold rating, suggesting a stable but not immediate growth trajectory.
In another report released on February 28, Wedbush also maintained a Hold rating on the stock with a $15.00 price target.
See today’s best-performing stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Zentalis Pharmaceuticals (ZNTL) Company Description:
Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. The company’s product candidate, ZN-c5, is an oral selective estrogen receptor degrader, or SERD, currently in a Phase 1/2 clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer. Its other products include ZN-c3, ZN-d5, and ZN-e4.
Read More on ZNTL:
- Zentalis price target raised to $15 from $12 at Wedbush
- Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
- Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
- Zentalis sees cash runway into 2026
- Zentalis announces anticipated upcoming milestones
